Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3720 Target Snapshot

ATP-citrate synthase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
758Compounds
52Assays
0Approved Drugs
749.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

ATP-citrate synthase shows approved-linked disease relevance led by Abnormal circulating lipid concentration. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P53396. Start with Abnormal circulating lipid concentration, then reuse UniProt P53396 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Abnormal circulating lipid concentration, then reuse UniProt P53396 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Abnormal circulating lipid concentration

ATP-citrate synthase shows approved-linked disease relevance led by Abnormal circulating lipid concentration. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Abnormal circulating lipid concentration because it currently carries approved-linked support. Linked drugs include BEMPEDOIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats ATP-citrate synthase as ChEMBL target CHEMBL3720, mapped to UniProt P53396. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
ATP-citrate synthase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3720
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P53396
ATP-citrate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether ATP-citrate synthase is the right protein anchor across sources, using UniProt P53396 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Abnormal circulating lipid concentration is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameATP-citrate synthase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP53396
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelATP-citrate synthase
UniProt AccessionP53396
Component TypeProtein
Sequence Length1101 aa

ATP-citrate synthase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as ATP-citrate synthase, mapped to UniProt P53396. Sequence length is 1101 aa.

Mapped IDP53396
Review nameATP-citrate synthase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

ATP-citrate synthase shows approved-linked disease relevance led by Abnormal circulating lipid concentration. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Abnormal circulating lipid concentration
1 linked drug · 1 direct · 1 efficacy
Linked drugBEMPEDOIC ACID
Approved-linked Approved
atherosclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugBEMPEDOIC ACID
Approved-linked Approved
cardiovascular disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBEMPEDOIC ACID
Approved-linked Approved
coronary artery disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBEMPEDOIC ACID
Approved-linked Approved
familial hypercholesterolemia
1 linked drug · 1 direct · 1 efficacy
Linked drugBEMPEDOIC ACID
Approved-linked Approved
Hypercholesterolemia
1 linked drug · 1 direct · 1 efficacy
Linked drugBEMPEDOIC ACID
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Abnormal circulating lipid concentration because it currently carries approved-linked support. Linked drugs include BEMPEDOIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAbnormal circulating lipid concentration
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50683.0
KI60.0
KD6.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5406616 8.68 IC50 2.1 Preclinical
CHEMBL5406616 8.66 Kd 2.2 Preclinical
CHEMBL5439664 7.16 IC50 69.7 Preclinical
CHEMBL399379 6.89 IC50 130.0 Preclinical
CHEMBL118715 6.82 IC50 150.0 Preclinical
CHEMBL400743 6.72 IC50 190.0 Preclinical
CHEMBL120302 6.66 Ki 220.0 Preclinical
CHEMBL2163366 6.66 Ki 220.0 Preclinical
CHEMBL5740498 6.56 IC50 275.0 Preclinical
CHEMBL5751874 6.56 IC50 275.0 Preclinical
Distribution

pChEMBL Value Distribution

112
5.0
23
5.5
29
6.0
66
6.5
4
7.0
0
7.5
0
8.0
3
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

52
Total Assays
651
Tested Compounds
1
Assay Types
Binding — 52 assays, 651 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 40 648 5.3
assay format 7 3 5.8
cell-based format 5 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine